Abstract
Introduction: Prostate cancer is the second most common cancer in men worldwide. In Brazil, regional disparities in incidences of intermediate and high-risk in late-diagnosed PC cases are expected. Objective: To investigate the clinical and demographic profiles of patients treated with metastatic castration-resistant prostate cancer (mCRPC) in Brazil, using real-world data from public databases. Method: Prostate cancer data from the Brazilian cancer registries were filtered from Brazilian public databases from 2008 to 2018. The number of health institutions and registries at a cancer public database were used to separate the Brazilian Federative Units into two comparison groups. mCRPC patients were estimated by using a combination of filters of staging and treatment (Tx, Nx and M1 + chemotherapy). The patients’ median age and the number and type of treatments were evaluated. Results: A total of 325,987 patients with prostate cancer and 5,367 patients with mCRPC were identified. The median age of the mCRPC patients was 63 years. The percentage of patients who underwent one, two or three treatments was 21.0%, 43.2% and 28.1%, respectively. In addition, management differences were noticed depending on the group analyzed. Conclusion: The results revealed regional discrepancies in the distribution of registered mCRPC patients in the Brazilian territory and in their treatment. This information can be used to strengthen the recently updated treatment and improve the palliative care offered. This work presents suggestions to improve specific prostate cancer databases.
Publisher
Revista Brasileira De Cancerologia (RBC)
Reference34 articles.
1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi: https://doi.org/10.3322/caac.21660
2. Instituto Nacional de Câncer. Estimativa 2023: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2022 [acesso 2023 abr 12]. Disponível em: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2023.pdf
3. Culp MBB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38-52. doi: https://doi.org/10.1016/j.eururo.2019.08.005
4. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012;13(8):790-801. doi: https://doi.org/10.1016/S1470-2045(12)70211-5
5. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243-62. doi: https://doi.org/10.1016/j.eururo.2020.09.042